A hopeful start to the week as @BioVie_Pharma showcases findings for bezesterim at the @ANAneurology conference. This follows an encouraging update from last month, when BioVie collaborated with researchers from the UCSF LIINC team to announce successful Phase II clinical trial outcomes for Long COVID.
The therapeutic mechanism of bezisterim is thought to combat the downstream inflammation caused by the lingering SARS-CoV-2 virus and its associated spike protein. Seeing these findings highlighted at such a prominent medical gathering is an incredibly welcome development.
As detailed in the official press release, an estimated 17 to 20 million adults in the U.S. are currently living with Long COVID, with 3.8 million of those individuals enduring severe limitations in their daily routines. Nearly 50 percent of people who contract the condition experience intermittent or continuous symptoms. Among the most widespread and debilitating issues are neurological and neuropsychiatric manifestations, which include fatigue, PEM, disrupted sleep, and a lasting impairment in memory and cognitive function. A leading hypothesis for these symptoms points to a combination of ongoing immune dysregulation and chronic innate inflammation. Furthermore, numerous investigators have reported observations in Long COVID patients that directly support the specific biological mechanisms bezisterim is intended to target. At present, patients have no FDA-approved treatment options for Long-COVID.
A frustrating reality is that certain physicians attending this event may still be unaware of Long COVID. Some might even doubt its legitimacy or incorrectly assume the illness is entirely psychological. However, widely disseminating concrete scientific evidence through esteemed associations and reputable organizations is the key to accelerating a much-needed shift in medical perspective.
This progress brings a great deal of optimism for today.
https://www.biospace.com/press-releases/biovie-presents-data-on-bezisterim-in-long-covid-at-the-2026-american-neurological-association-annual-meeting
The therapeutic mechanism of bezisterim is thought to combat the downstream inflammation caused by the lingering SARS-CoV-2 virus and its associated spike protein. Seeing these findings highlighted at such a prominent medical gathering is an incredibly welcome development.
As detailed in the official press release, an estimated 17 to 20 million adults in the U.S. are currently living with Long COVID, with 3.8 million of those individuals enduring severe limitations in their daily routines. Nearly 50 percent of people who contract the condition experience intermittent or continuous symptoms. Among the most widespread and debilitating issues are neurological and neuropsychiatric manifestations, which include fatigue, PEM, disrupted sleep, and a lasting impairment in memory and cognitive function. A leading hypothesis for these symptoms points to a combination of ongoing immune dysregulation and chronic innate inflammation. Furthermore, numerous investigators have reported observations in Long COVID patients that directly support the specific biological mechanisms bezisterim is intended to target. At present, patients have no FDA-approved treatment options for Long-COVID.
A frustrating reality is that certain physicians attending this event may still be unaware of Long COVID. Some might even doubt its legitimacy or incorrectly assume the illness is entirely psychological. However, widely disseminating concrete scientific evidence through esteemed associations and reputable organizations is the key to accelerating a much-needed shift in medical perspective.
This progress brings a great deal of optimism for today.
https://www.biospace.com/press-releases/biovie-presents-data-on-bezisterim-in-long-covid-at-the-2026-american-neurological-association-annual-meeting